Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infection

Nayan, Mohammad Ullah; Sillman, Brady; Hasan, Mahmudul; Deodhar, Suyash; Das, Srijanee; Sultana, Ashrafi; Nijenhuis, L. E.; Soriano, Vincent; Edagwa, Benson; Gendelman, Howard E.

doi:10.1016/j.addr.2023.115009

Cited by 17 publications

(5 citation statements)

References 164 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PK evaluation of this device in beagle dogs demonstrated a zero-order release kinetics of TAF (1.07 ± 0.02 mg/day) that sustained therapeutic TFV-DP levels in PBMCs for 40 days. The implant is currently in an early phase I clinical trial to assess its safety and tolerability [ 167 ]. The ability to remove the implant can be advantageous in the case of adverse reactions.…”

Section: La Arv Deliverymentioning

confidence: 99%

“…Furthermore, the rate of ISL release showed an increasing trend with its loading content. Several clinical trials involving ISL implants and oral regimens have been halted as reductions of the participants’ CD4+ T-cell and lymphocyte counts have been reported [ 167 ].…”

Section: La Arv Deliverymentioning

confidence: 99%

“…With a larger surface area, the nano-sized crystal improves the dissolution properties of the drugs, helping maintain a sufficient concentration for efficacy. The benefit of smaller particle size is also evident in the improved syringeability of the formulation [ 167 , 265 ].…”

Section: La Arv Deliverymentioning

confidence: 99%

See 2 more Smart Citations

Polymer Delivery Systems for Long-Acting Antiretroviral Drugs

Nayan,

Panja,

Sultana

et al. 2024

Pharmaceutics

Self Cite

View full text Add to dashboard Cite

The success of long-acting (LA) drug delivery systems (DDSs) is linked to their biocompatible polymers. These are used for extended therapeutic release. For treatment or prevention of human immune deficiency virus type one (HIV-1) infection, LA DDSs hold promise for improved regimen adherence and reduced toxicities. Current examples include Cabenuva, Apretude, and Sunlenca. Each is safe and effective. Alternative promising DDSs include implants, prodrugs, vaginal rings, and microarray patches. Each can further meet patients’ needs. We posit that the physicochemical properties of the formulation chemical design can optimize drug release profiles. We posit that the strategic design of LA DDS polymers will further improve controlled drug release to simplify dosing schedules and improve regimen adherence.

show abstract

Section: La Arv Deliverymentioning

confidence: 99%

Section: La Arv Deliverymentioning

confidence: 99%

See 1 more Smart Citation

Polymer Delivery Systems for Long-Acting Antiretroviral Drugs

Nayan,

Panja,

Sultana

et al. 2024

Pharmaceutics

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition to CAB/RPV, research focuses on alternative long-acting injectables, including long-active capsid inhibitors and long-acting slow-effective release antiretroviral therapy (LASER ART). LASER ART consists of uniform particles of solid prodrug nanocrystals that are stabilized by aqueous surfactant formulations [104,228].…”

Section: Challenges and Opportunities In Overcoming Hiv Drug Resistancementioning

confidence: 99%

The Phenomenon of Antiretroviral Drug Resistance in the Context of Human Immunodeficiency Virus Treatment: Dynamic and Ever Evolving Subject Matter

Apetroaei,

Velescu,

Nedea

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Human immunodeficiency virus (HIV) is a significant global health issue that affects a substantial number of individuals across the globe, with a total of 39 million individuals living with HIV/AIDS. ART has resulted in a reduction in HIV-related mortality. Nevertheless, the issue of medication resistance is a significant obstacle in the management of HIV/AIDS. The unique genetic composition of HIV enables it to undergo rapid mutations and adapt, leading to the emergence of drug-resistant forms. The development of drug resistance can be attributed to various circumstances, including noncompliance with treatment regimens, insufficient dosage, interactions between drugs, viral mutations, preexposure prophylactics, and transmission from mother to child. It is therefore essential to comprehend the molecular components of HIV and the mechanisms of antiretroviral medications to devise efficacious treatment options for HIV/AIDS.

show abstract

“…Elsulfavirine (VM-1500) inhibits reverse transcription (Nayan et al, 2023) and is a prodrug of VM-1500A Figure 17. It received approval in Russia in 2017, but it is still to be approved in the United States and Europe.…”

Section: Elsulfavirinementioning

confidence: 99%

Current insights and molecular docking studies of HIV‐1 reverse transcriptase inhibitors

Singh,

Kumar,

Arora

et al. 2023

Chem Biol Drug Des

View full text Add to dashboard Cite

Human immunodeficiency virus (HIV) causes acquired immunodeficiency syndrome (AIDS), a lethal disease that is prevalent worldwide. According to the Joint United Nations Programme on HIV/AIDS (UNAIDS) data, 38.4 million people worldwide were living with HIV in 2021. Viral reverse transcriptase (RT) is an excellent target for drug intervention. Nucleoside reverse transcriptase inhibitors (NRTIs) were the first class of approved antiretroviral drugs. Later, a new type of non‐nucleoside reverse transcriptase inhibitors (NNRTIs) were approved as anti‐HIV drugs. Zidovudine, didanosine, and stavudine are FDA‐approved NRTIs, while nevirapine, efavirenz, and delavirdine are FDA‐approved NNRTIs. Several agents are in clinical trials, including apricitabine, racivir, elvucitabine, doravirine, dapivirine, and elsulfavirine. This review addresses HIV‐1 structure, replication cycle, reverse transcription, and HIV drug targets. This study focuses on NRTIs and NNRTIs, their binding sites, mechanisms of action, FDA‐approved drugs and drugs in clinical trials, their resistance and adverse effects, their molecular docking studies, and highly active antiretroviral therapy (HAART).

show abstract

Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infection

Cited by 17 publications

References 164 publications

Polymer Delivery Systems for Long-Acting Antiretroviral Drugs

Polymer Delivery Systems for Long-Acting Antiretroviral Drugs

The Phenomenon of Antiretroviral Drug Resistance in the Context of Human Immunodeficiency Virus Treatment: Dynamic and Ever Evolving Subject Matter

Current insights and molecular docking studies of HIV‐1 reverse transcriptase inhibitors

Contact Info

Product

Resources

About